Literature DB >> 15316101

MAGE-A1 interacts with adaptor SKIP and the deacetylase HDAC1 to repress transcription.

Sandra Laduron1, Rachel Deplus, Sifang Zhou, Olga Kholmanskikh, Danièle Godelaine, Charles De Smet, S Diane Hayward, François Fuks, Thierry Boon, Etienne De Plaen.   

Abstract

MAGE-A1 belongs to a family of 12 genes that are active in various types of tumors and silent in normal tissues except in male germ-line cells. The MAGE-encoded antigens recognized by T cells are highly tumor-specific targets for T cell-oriented cancer immunotherapy. The function of MAGE-A1 is currently unknown. To analyze it, we attempted to identify protein partners of MAGE-A1. Using yeast two-hybrid screening, we detected an interaction between MAGE-A1 and Ski Interacting Protein (SKIP). SKIP is a transcriptional regulator that connects DNA-binding proteins to proteins that either activate or repress transcription. We show that MAGE-A1 inhibits the activity of a SKIP-interacting transactivator, namely the intracellular part of Notch1. Deletion analysis indicated that this inhibition requires the binding of MAGE-A1 to SKIP. Moreover, MAGE-A1 was found to actively repress transcription by binding and recruiting histone deacetylase 1 (HDAC1). Our results indicate that by binding to SKIP and by recruiting HDACs, MAGE-A1 can act as a potent transcriptional repressor. MAGE-A1 could therefore participate in the setting of specific gene expression patterns for tumor cell growth or spermatogenesis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15316101      PMCID: PMC514365          DOI: 10.1093/nar/gkh735

Source DB:  PubMed          Journal:  Nucleic Acids Res        ISSN: 0305-1048            Impact factor:   16.971


  61 in total

1.  The CoRNR motif controls the recruitment of corepressors by nuclear hormone receptors.

Authors:  X Hu; M A Lazar
Journal:  Nature       Date:  1999-11-04       Impact factor: 49.962

2.  E2F1 and E1A(12S) have a homologous activation domain regulated by RB and CBP.

Authors:  D Trouche; T Kouzarides
Journal:  Proc Natl Acad Sci U S A       Date:  1996-02-20       Impact factor: 11.205

3.  The CBP co-activator stimulates E2F1/DP1 activity.

Authors:  D Trouche; A Cook; T Kouzarides
Journal:  Nucleic Acids Res       Date:  1996-11-01       Impact factor: 16.971

4.  Disruption of the mouse necdin gene results in early post-natal lethality.

Authors:  M Gérard; L Hernandez; R Wevrick; C L Stewart
Journal:  Nat Genet       Date:  1999-10       Impact factor: 38.330

5.  Truncated mammalian Notch1 activates CBF1/RBPJk-repressed genes by a mechanism resembling that of Epstein-Barr virus EBNA2.

Authors:  J J Hsieh; T Henkel; P Salmon; E Robey; M G Peterson; S D Hayward
Journal:  Mol Cell Biol       Date:  1996-03       Impact factor: 4.272

6.  cDNA and protein characterization of human MAGE-10.

Authors:  D Rimoldi; S Salvi; D Reed; P Coulie; V C Jongeneel; E De Plaen; F Brasseur; A M Rodriguez; T Boon; J C Cerottini
Journal:  Int J Cancer       Date:  1999-09-09       Impact factor: 7.396

7.  Physical and functional interactions of neuronal growth suppressor necdin with p53.

Authors:  H Taniura; K Matsumoto; K Yoshikawa
Journal:  J Biol Chem       Date:  1999-06-04       Impact factor: 5.157

8.  Genomic libraries and a host strain designed for highly efficient two-hybrid selection in yeast.

Authors:  P James; J Halladay; E A Craig
Journal:  Genetics       Date:  1996-12       Impact factor: 4.562

9.  A new MAGE gene with ubiquitous expression does not code for known MAGE antigens recognized by T cells.

Authors:  S Lucas; F Brasseur; T Boon
Journal:  Cancer Res       Date:  1999-08-15       Impact factor: 12.701

10.  Structure and expression of the mouse necdin gene. Identification of a postmitotic neuron-restrictive core promoter.

Authors:  T Uetsuki; K Takagi; H Sugiura; K Yoshikawa
Journal:  J Biol Chem       Date:  1996-01-12       Impact factor: 5.157

View more
  35 in total

1.  The role of MAGEA2 in head and neck cancer.

Authors:  Chad A Glazer; Ian M Smith; Sheetal Bhan; Wenyue Sun; Steven S Chang; Kavita M Pattani; William Westra; Zubair Khan; Joseph A Califano
Journal:  Arch Otolaryngol Head Neck Surg       Date:  2011-03

2.  Expression of cancer-testis (CT) antigens in placenta.

Authors:  Achim A Jungbluth; Wilson A Silva; Kristin Iversen; Denise Frosina; Bushra Zaidi; Keren Coplan; Susannah K Eastlake-Wade; Sandra B Castelli; Giulio C Spagnoli; Lloyd J Old; Martin Vogel
Journal:  Cancer Immun       Date:  2007-08-24

Review 3.  Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy.

Authors:  Pierre G Coulie; Benoît J Van den Eynde; Pierre van der Bruggen; Thierry Boon
Journal:  Nat Rev Cancer       Date:  2014-02       Impact factor: 60.716

4.  Human MageB2 Protein Expression Enhances E2F Transcriptional Activity, Cell Proliferation, and Resistance to Ribotoxic Stress.

Authors:  Leticia Y Peche; María F Ladelfa; María F Toledo; Miguel Mano; Julieta E Laiseca; Claudio Schneider; Martín Monte
Journal:  J Biol Chem       Date:  2015-10-14       Impact factor: 5.157

5.  A phase 2 study of panobinostat with lenalidomide and weekly dexamethasone in myeloma.

Authors:  Ajai Chari; Hearn J Cho; Amishi Dhadwal; Gillian Morgan; Lisa La; Katarzyna Zarychta; Donna Catamero; Erika Florendo; Nadege Stevens; Daniel Verina; Elaine Chan; Violetta Leshchenko; Alessandro Laganà; Deepak Perumal; Anna Huo-Chang Mei; Kaity Tung; Jami Fukui; Sundar Jagannath; Samir Parekh
Journal:  Blood Adv       Date:  2017-08-21

6.  Cancer-testis antigens are predominantly expressed in uterine leiomyosarcoma compared with non-uterine leiomyosarcoma.

Authors:  Kunio Iura; Kenichi Kohashi; Nobuko Yasutake; Takeaki Ishii; Akira Maekawa; Hirofumi Bekki; Hiroshi Otsuka; Yuichi Yamada; Hidetaka Yamamoto; Yoshihiro Ohishi; Yoshihiro Matsumoto; Yukihide Iwamoto; Yoshinao Oda
Journal:  Oncol Lett       Date:  2017-10-26       Impact factor: 2.967

7.  MAGE-A1 expression is associated with good prognosis in neuroblastoma tumors.

Authors:  Elena Grau; Silvestre Oltra; Francisco Martínez; Carmen Orellana; Adela Cañete; Jose María Fernández; Miguel Hernández-Martí; Victoria Castel
Journal:  J Cancer Res Clin Oncol       Date:  2008-09-27       Impact factor: 4.553

8.  Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy.

Authors:  Richard A Morgan; Nachimuthu Chinnasamy; Daniel Abate-Daga; Alena Gros; Paul F Robbins; Zhili Zheng; Mark E Dudley; Steven A Feldman; James C Yang; Richard M Sherry; Giao Q Phan; Marybeth S Hughes; Udai S Kammula; Akemi D Miller; Crystal J Hessman; Ashley A Stewart; Nicholas P Restifo; Martha M Quezado; Meghna Alimchandani; Avi Z Rosenberg; Avindra Nath; Tongguang Wang; Bibiana Bielekova; Simone C Wuest; Nirmala Akula; Francis J McMahon; Susanne Wilde; Barbara Mosetter; Dolores J Schendel; Carolyn M Laurencot; Steven A Rosenberg
Journal:  J Immunother       Date:  2013-02       Impact factor: 4.456

9.  Reciprocal roles of SIRT1 and SKIP in the regulation of RAR activity: implication in the retinoic acid-induced neuronal differentiation of P19 cells.

Authors:  Moo-Rim Kang; Sang-Wang Lee; Elisa Um; Hyun Tae Kang; Eun Seong Hwang; Eun-Joo Kim; Soo-Jong Um
Journal:  Nucleic Acids Res       Date:  2009-11-24       Impact factor: 16.971

10.  Coordinated activation of candidate proto-oncogenes and cancer testes antigens via promoter demethylation in head and neck cancer and lung cancer.

Authors:  Ian M Smith; Chad A Glazer; Suhail K Mithani; Michael F Ochs; Wenyue Sun; Sheetal Bhan; Alexander Vostrov; Ziedulla Abdullaev; Victor Lobanenkov; Andrew Gray; Chunyan Liu; Steven S Chang; Kimberly L Ostrow; William H Westra; Shahnaz Begum; Mousumi Dhara; Joseph Califano
Journal:  PLoS One       Date:  2009-03-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.